Artivion, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows the company bought a business that makes aortic treatment products, expanding its medical device portfolio.
Shareholders voted on who runs the company and how much executives earn, keeping leadership accountable.
Reveals how much money the company made and spent in the first three months of 2026.
Company used a purchase option from 2019 to acquire Endospan after its product got FDA approval.
Shows the company's total revenue, profits, and financial health for all of 2025.
Announces final 2025 earnings numbers and how business performed in Q4.
Stocky reads Artivion, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Artivion, Inc.'s most recent tracked filing was a 8-K on 18 May 2026: Completes $175 million acquisition of Endospan Ltd..
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.